Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease

Carolina Di Somma, Annamaria Colao, Rosario Pivonello, Michele Klain, Antongiulio Faggiano, Francesca S. Tripodi, Bartolomeo Merola, Marco Salvatore, Gaetano Lombardi

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

BACKGROUND: Osteoporosis is common in patients with Cushing's disease and is likely due to an imbalance between bone formation and resorption. Alendronate is an aminobisphosphonate that is able to increase bone mass mainly by inhibiting bone resorption. OBJECTIVE: We have evaluated the effect of chronic treatment with alendronate on bone mineral density (BMD) in patients with Cushing's disease. PATIENTS: 39 patients with Cushing's disease entered this study. 39 age-, sex- and BMI-matched normals served as controls for baseline evaluation. The 39 patients were divided into four groups: 1) 10 patients with active disease treated with alendronate and ketoconazole; 2) 11 patients with inactive disease treated with alendronate; 3) 8 patients with active disease treated with ketoconazole alone, 4) 10 patients with inactive disease received no treatment. TREATMENT PROTOCOL: Alendronate was given for 12 months in a dose of 10 mg orally once daily after fasting at 0800h in the morning. Ketoconazole was given in a dose of 200-600mg orally daily, when pituitary surgery was unsuccessful. STUDY DESIGN: Lumbar spine (L1-L4) and femoral neck BMD, serum osteocalcin (OC), urinary cross-linked N-telopeptides of type I collagen (Ntx) levels were evaluated at study entry, in patients and controls, and were repeated after 6 and 12 months in the 39 patients. RESULTS: BMD values were lower in patients with Cushing's disease than in controls at both L1-L4 (0.72±0.4 vs. 1.01±0.6 g/cm2, P2, P

Original languageEnglish
Pages (from-to)655-662
Number of pages8
JournalClinical Endocrinology
Volume48
Issue number5
DOIs
Publication statusPublished - 1998

Fingerprint

Alendronate
Pituitary ACTH Hypersecretion
Osteoporosis
Ketoconazole
Bone Density
Bone Resorption
Femur Neck
Osteocalcin
Collagen Type I
Osteogenesis
Fasting
Spine

ASJC Scopus subject areas

  • Endocrinology

Cite this

Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. / Di Somma, Carolina; Colao, Annamaria; Pivonello, Rosario; Klain, Michele; Faggiano, Antongiulio; Tripodi, Francesca S.; Merola, Bartolomeo; Salvatore, Marco; Lombardi, Gaetano.

In: Clinical Endocrinology, Vol. 48, No. 5, 1998, p. 655-662.

Research output: Contribution to journalArticle

Di Somma, C, Colao, A, Pivonello, R, Klain, M, Faggiano, A, Tripodi, FS, Merola, B, Salvatore, M & Lombardi, G 1998, 'Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease', Clinical Endocrinology, vol. 48, no. 5, pp. 655-662. https://doi.org/10.1046/j.1365-2265.1998.00486.x
Di Somma, Carolina ; Colao, Annamaria ; Pivonello, Rosario ; Klain, Michele ; Faggiano, Antongiulio ; Tripodi, Francesca S. ; Merola, Bartolomeo ; Salvatore, Marco ; Lombardi, Gaetano. / Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. In: Clinical Endocrinology. 1998 ; Vol. 48, No. 5. pp. 655-662.
@article{d6c0de5cd21542dc8f14254ed7c6a5fb,
title = "Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease",
abstract = "BACKGROUND: Osteoporosis is common in patients with Cushing's disease and is likely due to an imbalance between bone formation and resorption. Alendronate is an aminobisphosphonate that is able to increase bone mass mainly by inhibiting bone resorption. OBJECTIVE: We have evaluated the effect of chronic treatment with alendronate on bone mineral density (BMD) in patients with Cushing's disease. PATIENTS: 39 patients with Cushing's disease entered this study. 39 age-, sex- and BMI-matched normals served as controls for baseline evaluation. The 39 patients were divided into four groups: 1) 10 patients with active disease treated with alendronate and ketoconazole; 2) 11 patients with inactive disease treated with alendronate; 3) 8 patients with active disease treated with ketoconazole alone, 4) 10 patients with inactive disease received no treatment. TREATMENT PROTOCOL: Alendronate was given for 12 months in a dose of 10 mg orally once daily after fasting at 0800h in the morning. Ketoconazole was given in a dose of 200-600mg orally daily, when pituitary surgery was unsuccessful. STUDY DESIGN: Lumbar spine (L1-L4) and femoral neck BMD, serum osteocalcin (OC), urinary cross-linked N-telopeptides of type I collagen (Ntx) levels were evaluated at study entry, in patients and controls, and were repeated after 6 and 12 months in the 39 patients. RESULTS: BMD values were lower in patients with Cushing's disease than in controls at both L1-L4 (0.72±0.4 vs. 1.01±0.6 g/cm2, P2, P",
author = "{Di Somma}, Carolina and Annamaria Colao and Rosario Pivonello and Michele Klain and Antongiulio Faggiano and Tripodi, {Francesca S.} and Bartolomeo Merola and Marco Salvatore and Gaetano Lombardi",
year = "1998",
doi = "10.1046/j.1365-2265.1998.00486.x",
language = "English",
volume = "48",
pages = "655--662",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease

AU - Di Somma, Carolina

AU - Colao, Annamaria

AU - Pivonello, Rosario

AU - Klain, Michele

AU - Faggiano, Antongiulio

AU - Tripodi, Francesca S.

AU - Merola, Bartolomeo

AU - Salvatore, Marco

AU - Lombardi, Gaetano

PY - 1998

Y1 - 1998

N2 - BACKGROUND: Osteoporosis is common in patients with Cushing's disease and is likely due to an imbalance between bone formation and resorption. Alendronate is an aminobisphosphonate that is able to increase bone mass mainly by inhibiting bone resorption. OBJECTIVE: We have evaluated the effect of chronic treatment with alendronate on bone mineral density (BMD) in patients with Cushing's disease. PATIENTS: 39 patients with Cushing's disease entered this study. 39 age-, sex- and BMI-matched normals served as controls for baseline evaluation. The 39 patients were divided into four groups: 1) 10 patients with active disease treated with alendronate and ketoconazole; 2) 11 patients with inactive disease treated with alendronate; 3) 8 patients with active disease treated with ketoconazole alone, 4) 10 patients with inactive disease received no treatment. TREATMENT PROTOCOL: Alendronate was given for 12 months in a dose of 10 mg orally once daily after fasting at 0800h in the morning. Ketoconazole was given in a dose of 200-600mg orally daily, when pituitary surgery was unsuccessful. STUDY DESIGN: Lumbar spine (L1-L4) and femoral neck BMD, serum osteocalcin (OC), urinary cross-linked N-telopeptides of type I collagen (Ntx) levels were evaluated at study entry, in patients and controls, and were repeated after 6 and 12 months in the 39 patients. RESULTS: BMD values were lower in patients with Cushing's disease than in controls at both L1-L4 (0.72±0.4 vs. 1.01±0.6 g/cm2, P2, P

AB - BACKGROUND: Osteoporosis is common in patients with Cushing's disease and is likely due to an imbalance between bone formation and resorption. Alendronate is an aminobisphosphonate that is able to increase bone mass mainly by inhibiting bone resorption. OBJECTIVE: We have evaluated the effect of chronic treatment with alendronate on bone mineral density (BMD) in patients with Cushing's disease. PATIENTS: 39 patients with Cushing's disease entered this study. 39 age-, sex- and BMI-matched normals served as controls for baseline evaluation. The 39 patients were divided into four groups: 1) 10 patients with active disease treated with alendronate and ketoconazole; 2) 11 patients with inactive disease treated with alendronate; 3) 8 patients with active disease treated with ketoconazole alone, 4) 10 patients with inactive disease received no treatment. TREATMENT PROTOCOL: Alendronate was given for 12 months in a dose of 10 mg orally once daily after fasting at 0800h in the morning. Ketoconazole was given in a dose of 200-600mg orally daily, when pituitary surgery was unsuccessful. STUDY DESIGN: Lumbar spine (L1-L4) and femoral neck BMD, serum osteocalcin (OC), urinary cross-linked N-telopeptides of type I collagen (Ntx) levels were evaluated at study entry, in patients and controls, and were repeated after 6 and 12 months in the 39 patients. RESULTS: BMD values were lower in patients with Cushing's disease than in controls at both L1-L4 (0.72±0.4 vs. 1.01±0.6 g/cm2, P2, P

UR - http://www.scopus.com/inward/record.url?scp=0031747924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031747924&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2265.1998.00486.x

DO - 10.1046/j.1365-2265.1998.00486.x

M3 - Article

C2 - 9666879

AN - SCOPUS:0031747924

VL - 48

SP - 655

EP - 662

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 5

ER -